In December 2023, Boston Scientific Corporation (NYSE: BSX) initiated the AVANT GUARD trial to evaluate the safety and ...
The med-tech company with approximately 9,400 employees in Minnesota posted profit and sales that beat Wall Street’s ...
Boston Scientific (BSX) shares fell 5% following news that the company has paused a study for its FARAPULSE PFA system due to ...
Despite a trial pause, Boston Scientific's impressive Q3 results and strategic expansions hint at a promising growth ...
Boston Scientific is keeping the ball rolling in pulsed field ablation, posting 177% electrophysiology growth in the third ...
Demand for the pulsed field ablation device drove the company’s electrophysiology sales up 177% in the third quarter compared ...
Boston Scientific reported third-quarter results that came in ahead of the consensus forecast, raising its 2024 guidance ...
Wells Fargo raised the firm’s price target on Boston Scientific (BSX) to $98 from $87 and keeps an Overweight rating on the shares. The ...
Boston Scientific stock pulled back from its run at a record high on Wednesday despite reporting a sweeping third-quarter beat.
Boston Scientific received FDA approval for its navigation-enabled Farawave Nav ablation catheter and clearance for new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback